Revolution Medicines (RVMD) Director Kim Lorence Sells $3.59M Stock

What Happened

• Kim Lorence H., a director of Revolution Medicines (RVMD), sold a total of 17,090 shares on September 8, 2026 in a series of open‑market transactions (transaction code S). The filings show total proceeds of $3,585,837, implying a weighted‑average sale price of roughly $209.8 per share.
• The sale was reported on Form 4 filed September 10, 2026. Individual lots included: 706 @ $206.60; 999 @ $207.33; 3,587 @ $208.55; 2,853 @ $209.56; 4,730 @ $210.50; 3,844 @ $211.36; and 371 @ $212.27. These disposals are routine sales (not purchases).

Key Details

• Transaction date: 2026-09-08; Form 4 filed: 2026-09-10 (appears timely — within the two business‑day Form 4 window).
• Total shares sold: 17,090; total proceeds: $3,585,837; weighted‑average price ≈ $209.8/share.
• Shares owned after transaction: not specified in the summary provided — see the full Form 4 for post‑transaction holdings.
• Notable footnotes: filing indicates some sales were executed in multiple trades at narrow price ranges (weighted averages reported) and that certain shares are/ were held by the Lorence Kim Revocable Trust. One footnote (F2) states the transaction was made pursuant to a 10b5‑1 trading plan adopted June 1, 2026.
• Transaction code: S = Sale.

Context

• Sales by directors are often routine portfolio-management transactions; they do not necessarily signal a change in company outlook. Because this filing notes a 10b5‑1 plan, some or all trades were pre‑arranged under that trading plan, which is designed to remove discretionary timing by the insider.
• For full details (exact post‑trade holdings, the full price-by-trade breakdown, and all footnotes), consult the original SEC Form 4 (Accession 0001193125-26-388156).